CRISPR Therapeutics (CRSP) CEO RSU Vesting Triggers 13,081-Share Tax Sale

Rhea-AI Filing Summary

Samarth Kulkarni, Chief Executive Officer and director of CRISPR Therapeutics AG (CRSP), had 25,000 restricted stock units vest on 08/16/2025, each converting to one common share. To satisfy tax withholding required by the company's RSU Settlement Policy, the reporting person sold 13,081 shares on 08/18/2025 at a price of $58.15 per share. After these transactions the reporting person directly beneficially owns 207,004 common shares and indirectly owns 85,622 common shares through the Kulkarni 2023 GRAT. The sale was described as mandated to cover tax withholding and not a discretionary trade.

Positive

• 25,000 RSUs vested, indicating executive compensation alignment tied to multi-year performance or tenure
• Significant continued ownership: 207,004 shares directly and 85,622 shares indirectly via the Kulkarni 2023 GRAT

Negative

• 13,081 shares sold on 08/18/2025 at $58.15 to satisfy tax withholding, reducing direct share count
• Sale reduces immediately liquid holdings though it was mandated for taxes rather than discretionary selling

Insights

Corporate Governance Expert

TL;DR Routine RSU vesting and a mandated tax-withholding sale by the CEO, preserving long-term ownership while satisfying tax obligations.

The filing documents a standard executive equity settlement: 25,000 RSUs vested and converted to common shares, followed by a company-policy-mandated sale of 13,081 shares to cover tax withholding. Reporting shows continued meaningful ownership both directly (207,004 shares) and indirectly via a GRAT (85,622 shares). This is a routine compensation-related disclosure and does not indicate voluntary disposal of shares for liquidity or signaling of a change in governance stance.

Executive Compensation/Tax Analyst

TL;DR Vesting-triggered tax withholding was executed by share sale; transaction aligns with standard RSU settlement practices and tax requirements.

The disclosure clarifies that the sale of 13,081 shares at $58.15 per share was specifically to meet the tax withholding obligation tied to RSU vesting, per the company's RSU Settlement Policy. The RSU award granted on August 16, 2022 fully vested on August 16, 2025. The treatment is consistent with common practices to net shares for taxes and does not reflect an independent decision to liquidate holdings.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kulkarni Samarth

(Last) (First) (Middle)

C/O CRISPR THERAPEUTICS

105 WEST FIRST STREET

(Street)

BOSTON MA 02127

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CRISPR Therapeutics AG [ CRSP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
08/16/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	08/16/2025		M		25,000	A	(1)	220,085	D
Common Shares	08/18/2025		S		13,081(2)	D	$58.15	207,004	D
Common Shares								85,622	I	The Kulkarni 2023 GRAT

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	08/16/2025		M			25,000	(3)	(3)	Common Shares	25,000	(1)	0	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.

2. Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.

3. This restricted stock unit award was granted on August 16, 2022 with respect to 25,000 Common Shares, with 100% of the shares vesting on August 16, 2025.

	/s/ Elizabeth Ryland Waldinger, attorney-in-fact	08/19/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Who filed the Form 4 for CRSP and what are their roles?

The Form 4 was filed for Samarth Kulkarni, who is listed as both Chief Executive Officer and a director of CRISPR Therapeutics AG.

How many RSUs vested and when did they vest?

25,000 restricted stock units vested on 08/16/2025, originally granted on August 16, 2022 with 100% vesting on that date.

How many shares were sold and at what price to cover taxes?

The reporting person sold 13,081 shares on 08/18/2025 at a price of $58.15 per share to satisfy the tax withholding obligation.

What are the reporting person’s beneficial holdings after these transactions?

After the transactions the reporting person directly beneficially owns 207,004 common shares and indirectly owns 85,622 common shares through the Kulkarni 2023 GRAT.

Was the sale a discretionary trade by the reporting person?

No. The sale was described as mandated by the company's RSU Settlement Policy to cover tax withholding and was not a discretionary trade.

When was the Form 4 filed/signed?

The document bears a signature block showing it was signed by an attorney-in-fact on 08/19/2025.